Description
Congestive heart failure, a condition caused by a malfunctioning heart that is unable to pump enough blood and oxygen to meet the body’s needs, is an increasingly important cause of cardiovascular morbidity and mortality. With improvements in the care of other cardiac conditions, more patients have developed dilated cardiomyopathy, which is the final common pathway for many cardiac illnesses and a common cause of congestive heart failure.
Kalorama Information’s Congestive Heart Failure, Major World Markets series looks at markets for CHF treatment in the United States, Europe, Japan and the Rest of the World. Volume II of this series looks at markets for device management of this disease in the following key categories:
- Pacemakers
- Left Ventricular Assistance Devices (LVADs)
- Implantable Cardioverter/Defibrillators (ICDs)
- Artificial Hearts
The report offers revenue breakdowns the following world markets:
- US
- Europe
- Japan
- Rest of World
In addition to market forecasts and current market information, this report contains a thorough review of products available on the market and profiles of key companies, including:
- Abbott Laboratories
- Abiomed, Inc.
- Ambu, USA
- Aortech International, plc
- Arrow International
- Atrium Medical Corporation
- ATS Medical, Inc.
- Bacchus Vascular, Inc.
- Berlin Heart AG
- Biophan Technologies, Inc.
- Biosensors International
- Biotronik, Inc.
- Boston Scientific
- CardiacAssist, Inc.
- Cardiac Science Corporation
- Cardiogenesis Corporation
- Cordis Corporation/Biologics Delivery Systems
- CoreValve, Inc.
- CryoCath Technologies, Inc.
- Cryocor, Inc.
- Datascope
- Defibtech, LLC
- Deltex Medical
- Heartlab
- Impulse Dynamics USA, Inc.
- MedicalCV, Inc.
- Medtronic, Inc.
- Orqis Medical Corporation
- Sorin SpA
- Stereotaxis, Inc.
- St. Jude Medical, Inc.
- Teleflex Medical
- Terumo Heart, Inc.
- Thoratec Corporation
- Ventracor, Inc.
- Volcano Corporation
As part of Kalorama Information’s methodology, analyst estimates are computed with intensive research of secondary data and literature, and primary research involving interviews of experts are used to test assumptions and validate models.
Product managers, business development executives, marketing executives and planners are among those who will benefit from this resource.
License Note: Kalorama Information’s listed default price on its information products reflects a single user license only. Purchasing a departmental license (up to 10 users at one location) or a global site license (entire company) permits multiple individuals in the company to benefit from this resource.
Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY
- Background
- Scope and Methodology
- Size and Growth of Market
CHAPTER TWO: OVERVIEW OF CHF
- Background
- Pathophysiology
- Types of Heart Failure
- Left Ventricular (LV) Failure
- Right Ventricular (RV) Failure
- Systolic Dysfunction
- Diastolic Dysfunction
- High Output Failure
- Theories of Congestive Heart Failure
- Hemodynamic Response Theory
- Neurohormonal Response Theory
- Renal Response Theory
- Conditions Leading to Congestive Heart Failure
- Myocardial Infarction
- Hypertension
- Cardiomyopathy
- Atrial Fibrillation
- Other Risk Factor
- Diagnosis of Congestive Heart Failure
- Classification of Congestive Heart Failure Patients
- Epidemiology
- United States
- Europe
- Japan
CHAPTER THREE: DEVICE TREATMENT OF CONGESTIVE HEART FAILURE
- Artificial Pacemaker
- Ventricular Assist Devices (VADs)
- Total Artificial Hearts (TAHs)
- American College of Cardiology Guideline
CHAPTER FOUR: CONGESTIVE HEART FAILURE PATIENT MANAGEMENT
- Guidelines for Management of Chronic Heart Failure
- Strategies to Maintain Quality Patient Care and Contain Costs
CHAPTER FIVE: WORLD MARKETS
- United States
- Europe
- Japan
CHAPTER SIX: COMPANY PROFILES
- Abbott Laboratories
- Abiomed, Inc.
- Ambu, USA
- Aortech International, plc
- Arrow International
- Atrium Medical Corporation
- ATS Medical, Inc.
- Bacchus Vascular, Inc.
- Berlin Heart AG
- Biophan Technologies, Inc.
- Biosensors International
- Biotronik, Inc.
- Boston Scientific
- CardiacAssist, Inc.
- Cardiac Science Corporation
- Cardiogenesis Corporation
- Cordis Corporation/Biologics Delivery Systems
- CoreValve, Inc.
- CryoCath Technologies, Inc.
- Cryocor, Inc.
- Datascope
- Defibtech, LLC
- Deltex Medical
- Heartlab
- Impulse Dynamics USA, Inc.
- MedicalCV, Inc.
- Medtronic, Inc.
- Orqis Medical Corporation
- Sorin SpA
- Stereotaxis, Inc.
- St. Jude Medical, Inc.
- Teleflex Medical
- Terumo Heart, Inc.
- Thoratec Corporation
- Ventracor, Inc.
- Volcano Corporation
CHAPTER SEVEN: STRATEGIC CONCLUSIONS
- First Conclusion
- Second Conclusion
- Implications:
- Third Conclusion
- Implications:
- Fourth Conclusion
- Implications:
- Fifth Conclusion
- Implications:
- Sixth Conclusion
- Implications:
- Seventh Conclusion
- Implications:
- Eighth Conclusion
- Implications:
APPENDIX A
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
- Figure 1-1: Incidence of Congestive Heart Failure Cases in the Major World
- Healthcare Markets: 2007 – 2017
- Figure 1-2: Prevalence of Congestive Heart Failure Cases in the Major World
- Healthcare Markets: 2007 – 2017
- Table 1-1: The Estimated Markets for Devices Used to Treat CHF in the Major
- World Healthcare Markets by Geographic Segment
- Figure 1-3 Trending in the Estimated Markets for Devices Used to Treat CHF in the Major World Healthcare Markets by Geographic Segment
- Figure 1-4: Distribution of the Estimated Markets for Devices Used to Treat CHF in the Major World Healthcare Markets by Geographic Segment
CHAPTER TWO: OVERVIEW OF CHF
- Table 2-1: International Cardiovascular Disease (CVD) Statistics
- Table 2-2: United States CHF Statistics: 2004
- Table 2-3: CHF Data Sources
- Table 2-4: Common Contributors to Congestive Heart Failure
- Figure 2-1: Incidence and Prevalence of Congestive Heart Failure In the World’s Major Healthcare Markets: 2007 – 2017
- Figure 2-2: Incidence Rates of Congestive Heart Failure in the Major World
- Healthcare Markets: 200l – 2017 (Cases per Million Population)
- Figure 2-3: Prevalence Rates of Congestive Heart Failure in the Major World
- Healthcare Markets: 2007 – 2017 (Cases per Million Population)
- Figure 2-4: Percentage Breakdown of Deaths from Cardiovascular Diseases: 2003
- Table 2-5: Incidence and Prevalence of CHF in the United States: 2007 – 2017
- Figure 2-5: Incidence and Prevalence of CHF in the United States: 2007 – 20017
- Figure 2-6: The Distribution of Congestive Heart Failure In the Five Major European Healthcare Markets: 2007
- Table 2-6: Incidence and Prevalence of CHF in the Major Healthcare Markets of Europe: 2007 – 2017 (Thousands)
- Figure 2-7: Incidence and Prevalence of CHF in the Major Healthcare Markets of Europe: 2007 – 20017 (Thousands)
- Table 2-7: Incidence and Prevalence of CHF in Japan: 2007 – 2017
- Figure 2-8: Incidence and Prevalence of CHF in Japan: 2007 – 20017
CHAPTER THREE: DEVICE TREATMENT OF CONGESTIVE HEART FAILURE
- Table 3-1: Key Implantable Heart Pacing Devices
- Table 3-2: Vascular Assist Devices
- Table 3-3: Total Artificial Heart Devices
- Table 3-4: Facilities Authorized to Performs Total Artificial Heart Implants
CHAPTER FOUR: CONGESTIVE HEART FAILURE PATIENT MANAGEMENT
- Figure 4-1: ACC/AHA Guideline Summary for Recommended Therapy of Congestive Heart Failure by Stage of the Disease
- Table 4-1: ACC/AHA Staging of Congestive Heart Failure
- Table 4-2: 2005 ACC/AHA Guidelines for Evaluation and Therapy for Congestive Heart Failure:
CHAPTER FOUR: CONGESTIVE HEART FAILURE MARKETS
- Table 5-1: The Estimated Markets for Devices Used to Treat CHF in the Major World Healthcare Markets by Geographic Segment
- Figure 5-1: Trending in the Estimated Markets for Devices Used to Treat CHF in the Major World Healthcare Markets by Geographic Segment
- Figure 5-2: Distribution of the Estimated Markets for Devices Used to Treat CHF in the Major World Healthcare Markets by Geographic Segment
- Table 5-2: The Estimated Markets for Devices Used to Treat CHF in the Major
- World Healthcare Markets by Device Segment
- Figure 5-3: Trending in the Estimated Markets for Devices to Treat CHF in the
- Major World Healthcare Markets by Device Segment
- Figure 5-4: Distribution of the Estimated Markets for Devices to Treat CHF in the Major World Healthcare Markets by Device Segment
- Table 5-3: The Estimated Markets for Devices Used to Treat CHF in the
- United States Healthcare Market by Device Segment (Pacemakers, ICDs,
- LVADs, and TAHs)
- Figure 5-5: Trending in the Estimated Markets for Devices Used to Treat CHF in the United States Healthcare Market by Device Segment
- Figure 5-6: Distribution of the Estimated Markets for Devices Used to Treat
- CHF in the United States Healthcare Market by Device Segment
- Table 5-4: The Estimated Markets for Devices Used to Treat CHF in the
- Five Major European Healthcare Markets by Device Segment
- Figure 5-7: Trending the Estimated Markets for Devices Used to Treat CHF in the Five Major European Healthcare Markets by Device Segment
- Figure 5-8: Distribution of the Estimated Markets for Devices Used to Treat CHF in the Five Major European Healthcare Markets by Device Segment
- Table 5-5: The Estimated Markets for Devices Used to Treat CHF in the Japanese
- Healthcare Market by Device Segment
- Figure 5-9: Trending in the Estimated Markets for Devices Used to Treat
- CHF in the Japanese Healthcare Market by Device Segment
- Figure 5-10: Distribution of the Estimated Markets for Devices Used to Treat CHF in the Japanese Healthcare Market by Device Segment
